• Amberg, S.M., Snyder, B., Vliet-Gregg, P.A., Tarcha, E.J., Posakony, J., Bedard, K.M., Heald, A.E., 2022. Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults. Antimicrob Agents Chemother, 10.1128/aac.00951-22, e0095122.

  • Cheng, H.Y., French, C.E., Salam, A.P., Dawson, S., Mcaleenan, A., Mcguinness, L.A., Savovic, J., Horby, P.W., Sterne, J.a.C., 2022. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies(1). Emerg Infect Dis, 28, 1559-1568.

  • Eberhardt, K.A., Mischlinger, J., Jordan, S., Groger, M., Gunther, S., Ramharter, M., 2019. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. Int J Infect Dis, 87, 15-20.

  • Feld, J.J., Hoofnagle, J.H., 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436, 967-972.

  • Garry, R.F., 2023. 50 Years of Lassa Fever Research. Curr Top Microbiol Immunol, 440, 1-22.

  • Grant, D.S., Samuels, R.J., Garry, R.F., Schieffelin, J.S., 2023. Lassa Fever Natural History and Clinical Management. Curr Top Microbiol Immunol, 440, 165-192.

  • Groger, M., Akhideno, P., Kleist, C.J., Babatunde, F.O., Edeawe, O., Hinzmann, J., Akhigbe, T., Nwatuzor, J., Eifediyi, G., Muller, J., Hinrichs M., Pahlmann M., Sarpong F.N., Wagner C., Thielebein A., Aihonwalan L., Koch T., Riedner M., Ogbaini-Emovon E., Okogbenin S., Gunther S., Wicha S.G., Ramharter M., Oestereich L., Duraffour S., Erameh C., 2023. Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Clin Infect Dis, 76, e841-e848.

  • Hu X, Bai X, Tian F, Xing Y, Shi Y, Tong Y, Zhong J. 2024. A novel bsl-2 lassa virus reverse genetics system modelling the complete viral life cycle. Emerg Microbes Infect, 13: 2356149.

  • Larson, R.A., Dai, D., Hosack, V.T., Tan, Y., Bolken, T.C., Hruby, D.E., Amberg, S.M., 2008. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol, 82, 10768-10775.

  • Li C, Luo F. 2025. The first imported case of lassa fever in china: A case description. Quant Imaging Med Surg, 15: 152 1066-1072.

  • Liu, Y., Guo, J., Cao, J., Zhang, G., Jia, X., Wang, P., Xiao, G.,Wang, W., 2021. Screening of Botanical Drugs against Lassa Virus Entry. J Virol, 95, e02429-20.

  • Madu, I.G., Files, M., Gharaibeh, D.N., Moore, A.L., Jung, K.H., Gowen, B.B., Dai, D., Jones, K.F., Tyavanagimatt, S.R., Burgeson, J.R., Korth, M.J., Bedard, K.M., Iadonato, S.P., Amberg, S.M., 2018. A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog, 14, e1007439.

  • Raabe, V.N., Kann, G., Ribner, B.S., Morales, A., Varkey, J.B., Mehta, A.K., Lyon, G.M., Vanairsdale, S., Faber, K., Becker, S., et al., 2017. Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. Clin Infect Dis, 65, 855-859.

  • Ran Q, Chen H, Huang L, Meng L, Chen Z, Ren L, Du Q, Zhang D, Li C, Zheng Y. 2024. The first case of Lassa fever in China. Electronic Journal of Emerging Infectious Diseases, 9: 1-5. (In Chinese).

  • Wang, P., Liu, Y., Zhang, G., Wang, S., Guo, J., Cao, J., Jia, X., Zhang, L., Xiao, G., Wang, W., 2018. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. J Virol, 92, e00954-18.

  • Westover, J.B., Bailey, K.W., Wasson, S.R., Boardman, K.M., Lustig, K.H., Amberg, S.M., Gowen, B.B., 2024. Coadministration of LHF-535 and favipiravir protects against experimental Junin virus infection and disease. Antiviral Res, 229, 105952.

  • Zhang, G., Cao, J., Cai, Y., Liu, Y., Li, Y., Wang, P., Guo, J., Jia, X., Zhang, M., Xiao, G., Guo, Y., Wang, W., 2019. Structure-activity relationship optimization for lassa virus fusion inhibitors targeting the transmembrane domain of GP2. Protein Cell, 10, 137-142.

  • Zhang, Z., Takenaga, T., Fehling, S.K., Igarashi, M., Hirokawa, T., Muramoto, Y., Yamauchi, K., Onishi, C., Nakano, M., Urata, S., Groseth, A., Strecker, T., Noda, T., 2024. Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entry. J Virol, 98, e0071424.